Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of “Hold” by Analysts
by Jessica Moore · The Cerbat GemRezolute, Inc. (NASDAQ:RZLT – Get Free Report) has received an average recommendation of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $8.00.
A number of equities analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $5.00 target price on shares of Rezolute in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a research note on Thursday, January 22nd. Finally, Wedbush raised shares of Rezolute from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $5.00 in a report on Wednesday, March 25th.
Get Our Latest Stock Analysis on Rezolute
Rezolute Stock Performance
RZLT stock opened at $3.37 on Thursday. The company has a market capitalization of $322.51 million, a price-to-earnings ratio of -3.62 and a beta of 0.65. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The stock has a fifty day moving average of $3.20 and a 200-day moving average of $5.18.
Rezolute (NASDAQ:RZLT – Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06). Equities analysts predict that Rezolute will post -0.68 EPS for the current year.
Institutional Investors Weigh In On Rezolute
Several institutional investors have recently made changes to their positions in RZLT. BNP Paribas Financial Markets bought a new position in shares of Rezolute in the second quarter worth $25,000. ExodusPoint Capital Management LP bought a new stake in shares of Rezolute during the 4th quarter valued at $25,000. HB Wealth Management LLC purchased a new stake in Rezolute during the 4th quarter worth about $26,000. Fifth Third Wealth Advisors LLC purchased a new stake in Rezolute during the 4th quarter worth about $29,000. Finally, Hsbc Holdings PLC bought a new position in Rezolute in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 82.97% of the company’s stock.
Rezolute Company Profile
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.